
Sean E O'brien

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10940789/publications.pdf Version: 2024-02-01



SEAN E O'RDIEN

#	Article	IF	CITATIONS
1	Targeting the nucleolus for cancer-specific activation of p53. Drug Discovery Today, 2014, 19, 259-265.	6.4	40
2	Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Letters, 2012, 322, 113-118.	7.2	67
3	Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells. PLoS ONE, 2012, 7, e49193.	2.5	51
4	Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics. ACS Medicinal Chemistry Letters, 2012, 3, 602-606.	2.8	111
5	CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy. Molecular Cancer Therapeutics, 2012, 11, 994-1005.	4.1	96
6	Synthesis and SAR of inhibitors of protein kinase CK2: Novel tricyclic quinoline analogs. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 45-48.	2.2	16
7	Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3327-3331.	2.2	31
8	Unprecedented Selectivity and Structural Determinants of a New Class of Protein Kinase CK2 Inhibitors in Clinical Trials for the Treatment of Cancer. Biochemistry, 2011, 50, 8478-8488.	2.5	154
9	7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: A novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6687-6692.	2.2	50
10	Discovery and SAR of 5-(3-Chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer. Journal of Medicinal Chemistry, 2011, 54, 635-654.	6.4	259
11	Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Molecular and Cellular Biochemistry, 2011, 356, 37-43.	3.1	130
12	Novel potent pyrimido[4,5-c]quinoline inhibitors of protein kinase CK2: SAR and preliminary assessment of their analgesic and anti-viral properties. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1687-1691.	2.2	28
13	Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth. Cancer Research, 2011, 71, 1418-1430.	0.9	482
14	CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy. Cancer Research, 2010, 70, 10288-10298.	0.9	449
15	Abstract 2763: Utility of clinical biomarkers for detecting protein kinase CK2 inhibition: A report from the phase I trial of CX-4945. Cancer Research, 2010, 70, 2763-2763.	0.9	1